DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



An fMRI Study Of Brain Response In Patients With Fibromyalgia

Information source: Pfizer
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Fibromyalgia

Intervention: Placebo, then pregabalin (Drug); Pregabalin, then placebo (Drug)

Phase: Phase 1

Status: Not yet recruiting

Sponsored by: Pfizer

Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer

Overall contact:
Pfizer CT.gov Call Center, Phone: 1-800-718-1021

Summary

To explore how pregabalin works in patients with fibromyalgia by evaluating brain imaging signals. To find out whether fMRI (functional magnetic resonance imaging) is an efficient way to show whether new pain medications are effective in treating fibromyalgia.

Clinical Details

Official title: A Double-Blind, Placebo-Controlled Cross-Over Study In Fibromyalgia Subjects To Examine Effects Of Pregabalin On Brain Reponse To Mechanical Pain As Assessed By Functional Magnetic Resonance Imaging, Proton Magnetic Responance Spectroscopy And Subjective Ratings

Study design: Other, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Crossover Assignment, Pharmacodynamics Study

Primary outcome:

Magnetic resonance imaging will be used to measure brain glutamine and glutamate levels.

fMRI brain activation signals will be evaluated across the whole brain and in defined brain regions in response to blunt pressure pain and to control visual stimuli.

Secondary outcome:

Pain will be evaluated using the Gracely Box Scales several times during each imaging session.

The modified Brief Inventory daily pain diary will be used to evaluate clinical pain.

The Short-Form McGill Pain Questionnaire will be used to evaluate pain.

The Hospital Anxiety and Depression Scale will be used to evaluate anxiety and depression levels.

The Pain Catastrophizing Scale will be used to evaluate the extent of catastrophizing.

Eligibility

Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Women must have pain due to fibromyalgia

- Fibromyalgia must have been diagnosed at least 6 months prior to be eligible for this

study

Exclusion Criteria:

- Patients with severe depression or other serious illness, who are left-handed, or who

are pregnant or nursing are not eligible for this study.

Locations and Contacts

Pfizer CT.gov Call Center, Phone: 1-800-718-1021

Additional Information

To obtain contact information for a study center near you, click here.

Starting date: November 2008
Ending date: December 2009
Last updated: October 24, 2008

Page last updated: November 03, 2008

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012